BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-391@pharmaconomics
DTSTAMP:20260707T033826Z
DTSTART;VALUE=DATE:20260212
DTEND;VALUE=DATE:20260213
SUMMARY:BBIO Phase 3 — infigratinib
DESCRIPTION:Phase 3 trial results for infigratinib in achondroplasia are due Feb 12\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1743881/000114036126004995/ef20065539_ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/391
URL:https://pharmaconomics.com/e/391
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BBIO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR